Trials / Completed
CompletedNCT02823951
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 479 (actual)
- Sponsor
- IMS HEALTH GmbH & Co. OHG · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the proportion of patients who demonstrate no medical need to discontinue therapy among DMT-naïve patients with relapsing forms of multiple sclerosis after 1 year of treatment with Rebif 44 mcg tiw or with Tecfidera 240 mg bid based on real-world data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebif | |
| DRUG | Tecfidera |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-04-01
- Completion
- 2018-02-01
- First posted
- 2016-07-06
- Last updated
- 2018-03-01
Locations
23 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02823951. Inclusion in this directory is not an endorsement.